v3.25.2
Discontinued operations - Details of the net gain of the sale of activities (Details) - CHF (SFr)
3 Months Ended 6 Months Ended 18 Months Ended
Apr. 02, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Neurosterix US Holdings LLC            
Disclosure            
Percentage of equity interest received 20.00%          
Discontinued operations as disclosed below            
Disclosure            
Cash in from Neurosterix Pharma Sarl sale SFr 5,000,000   SFr 5,000,000   SFr 5,000,000 SFr 5,000,000
Fair value of Neurosterix US Holdings LLC's participation     9,428,400   9,428,400 9,400,000
Net gain on Neurosterix Pharma Sarl derecognition (IFRS 10)     539,250   539,250  
Retirement benefit obligation of employees leaving the Group (IAS 19)     433,791   433,791  
Fair value of service agreement     182,348   182,348  
Net debt liabilities related to Neurosterix Pharma Sarl (IFRS 16)     11,144   11,144  
Other consideration   SFr 117,747   SFr 117,747    
Total disposal consideration     15,594,933   15,594,933  
Investment in Neurosterix Pharma Sarl     (20,000)   (20,000)  
Legal fees paid for Neurosterix Transaction     (26,653)   (454,964)  
Accelerating vesting ESOP/DSPPP     (1,158,069)   (1,158,069)  
Total costs related to activities sold     (1,204,722)   (1,633,033)  
Net gain on sale before income tax   117,747 14,390,211 117,747 13,961,900  
Net gain on sale after income tax   SFr 117,747 SFr 14,390,211 SFr 117,747 SFr 13,961,900 SFr 14,100,000
Discontinued operations as disclosed below | Neurosterix US Holdings LLC            
Disclosure            
Percentage of equity interest received 20.00%